Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06617169

Title field or adapter rule

{'original_value': 'Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:26.647281+00:00

Published At

2026-09-03T00:00:00+00:00

Record Updated At

2026-09-03

Source Retrieved At

2026-10-31T22:17:58.991924+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Solid Tumor, Adult", "Bladder Cancer", "Urothelial Carcinoma", "Triple-negative Breast Cancer", "Lung Cancer", "Colorectal Cancer", "Gastric Cancer", "Ovarian Cancer", "Pancreatic Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-03", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06617169"

protocolSection.identificationModule.officialTitle

"Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Solid Tumor, Adult (protocolSection.conditionsModule.conditions)
• Bladder Cancer (protocolSection.conditionsModule.conditions)
• Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
• Triple-negative Breast Cancer (protocolSection.conditionsModule.conditions)
• Lung Cancer (protocolSection.conditionsModule.conditions)
• Colorectal Cancer (protocolSection.conditionsModule.conditions)
• Gastric Cancer (protocolSection.conditionsModule.conditions)
• Ovarian Cancer (protocolSection.conditionsModule.conditions)
• Pancreatic Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Level 0 - MNPR-101-PCTA-177Lu 480 MBq', 'Level 1 - MNPR-101-PCTA-177Lu 960 MBq', 'Level 2 - MNPR-101-PCTA-177Lu 1440 MBq', 'Level 3 - MNPR-101-PCTA-177Lu 1920 MBq', 'Level 4 - MNPR-101-PCTA-177Lu 2240 MBq'], 'description': 'MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes, followed by a normal saline flush. Dosing will occur on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.', 'name': 'MNPR-101-PCTA-177Lu', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• MNPR-101-PCTA-177Lu (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.